Objectives: To determine the effects of lixisenatide, a new once-daily (QD) glucagon-like peptide-1 receptor agonist, on postprandial glucose (PPG) and gastric emptying, and the relationship between these effects in patients with type 2 diabetes mellitus (T2DM). Methods: Data were obtained from a randomized, double-blind, placebo-controlled, parallel-group study with treatment duration of 28 days in patients with T2DM receiving ≤ 2 oral antidiabetic drugs. Lixisenatide was injected subcutaneously using an ascending dose range (5-20 μg) increased every fifth day in increments of 2.5 μg. Blood glucose was determined before and after three standardized meals (breakfast, lunch, and dinner). Gastric emptying of the standardized breakfast was determined by a 
Introduction
Glucagon-like peptide-1 (GLP1) receptor agonists are now used widely in the management of type 2 diabetes (T2DM) [1] . These agents have beneficial effects on both fasting and postprandial glycemia, with concomitant improvements in 'average' glycemic control, as assessed by glycated hemoglobin (HbA 1c ) [1] [2] [3] [4] . As a class, GLP1 receptor agonists are known to simultaneously stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release [1] [2] [3] . This glucose dependency means that, unlike with insulin or insulin secretagogues (sulfonylurea) therapy, the risk of hypoglycemia is low. Moreover, the use of GLP-1 agonists is associated with weight loss, rather than the weight gain that is often observed with insulin therapy.
There are substantial differences between GLP-1 receptor agonists (currently available or in development) in terms of their duration of action and propensity for gastrointestinal effects following subcutaneous administration [3] . GLP-1 receptor agonists do not improve glycemia solely as a result of their effect on islet cell function in that they also slow gastric emptying [4, 5] . The latter is known to be an important determinant of postprandial glycemic excursions in healthy individuals [6] and in patients with T2DM [7, 8] . Slowing gastric emptying prolongs absorption of meal-derived glucose and has the capacity to blunt postprandial glucose (PPG) excursions [8, 9] . The rate of gastric emptying varies widely between healthy individuals [10] , and in patients with long-standing T2DM there is a high prevalence of delayed, and occasionally more rapid, gastric emptying, so that the inter-individual variation is even greater among these patients [11] . Importantly, the effects of exogenous GLP-1 on PPG and insulin appear to be related to the magnitude of slowing of gastric emptying [9, 12, 13] . Moreover, this slowing is dependent on the baseline rate of gastric emptying, so that when emptying is already slow, GLP-1 has little, if any, effect [9, 12] . A recent study suggests that there may be rapid tachyphylaxis to the slowing of gastric emptying by exogenous GLP-1 [14] . When two standardized liquid test meals were given to healthy subjects at an interval of 4 h during a continuous, intravenous GLP-1 infusion, GLP-1 delayed emptying of both drinks substantially, but the magnitude of this slowing was less with the second drink [14] . There is evidence for tachyphylaxis of the slowing of gastric emptying with marketed longer-acting GLP-1 receptor agonists, liraglutide once-daily (QD) and exenatide once-weekly (LAR); this is not observed with the shorter-acting agent exenatide twice-daily (BID) [5, 15, 16] . Hence, there appear to be substantial differences between GLP-1 receptor agonists regarding their effect on gastric emptying, which is relevant to their impact on HbA 1c and, particularly, postprandial glycemia.
Lixisenatide is a new once-daily GLP-1 receptor agonist. In a doseranging study in patients with T2DM inadequately controlled with metformin, lixisenatide at a dose of 20 μg QD demonstrated the best efficacy-to-tolerability ratio [17] . Lixisenatide has demonstrated efficacy as monotherapy, in combination with oral antidiabetic drugs, and as add-on to basal insulin, with particular efficacy in reducing PPG excursions [18] [19] [20] [21] [22] [23] [24] [25] [26] The objective of the current analysis was to determine the effects of lixisenatide 20 μg QD administered for 28 days on the blood glucose response to a standardized breakfast, lunch, and dinner, and evaluate the relationship between the effects of lixisenatide on postprandial blood glucose with those on gastric emptying in patients with T2DM.
Materials and methods
Presented data were derived from study ACT6011, which was a randomized, placebo-controlled, double-blind, parallel-group design study with a 28-day treatment duration, involving three centers in South Africa. The study was approved by the relevant institutional review boards or ethics committees and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All patients provided written informed consent prior to their participation. Safety and tolerability were monitored throughout the study. Adverse events reported spontaneously by the subject or observed by the investigator were recorded.
Study objectives
The objectives of this study were to assess the effect of lixisenatide on postprandial blood glucose after a standardized breakfast, lunch, and dinner, and on gastric emptying, C-peptide, serum insulin and glucagon concentration after a standardized breakfast, fasting blood glucose (FBG), HbA 1c , as well as safety and tolerability. The relationship between the change in area under the curve (AUC) for PPG and half-life of gastric emptying were assessed in a post-hoc linear regression analysis.
Patients
Males and females, 18-70 years old, body mass index (BMI) ≤35 kg/m 2 , with stable T2DM treated with up to two oral antidiabetic drugs (metformin and/or sulfonylurea) under routine care of a physician for diabetes, with a stable diabetic prescription history (i.e. within the previous 3 months and including adherence to 'reasonable' dietary guidelines), reasonable glucose control and HbA 1c ≥7.0% and ≤10.0% were eligible for inclusion. Exclusion criteria included: evidence or history of renal, hepatic or cardiovascular disease, pancreatitis, gastric surgery, clinically relevant gastrointestinal disease (including known gastroparesis), previous exposure to GLP-1 receptor agonists, insulin use within the preceding 3 months, use of thiazolidinediones or drugs potentially affecting either insulin secretion or gastrointestinal motility (except beta-blockers and sulfonylureas).
Protocol
Data were derived from participants (hospitalized from the evening of Day−2 to the morning of Day 29) randomized to subcutaneous once-daily lixisenatide or placebo administered in the morning on Days 1 to 28. An additional lixisenatide twice-daily (morning and evening) treatment arm was included in the original study but these data were not included in the current analysis, given that lixisenatide 20 μg QD has been subsequently demonstrated to provide the best efficacy-to-tolerability ratio [17] . Lixisenatide was injected at an initial dose of 5 μg QD and the dose per injection was increased in increments of 2.5 μg every fifth day, to a maximum level of 20 μg QD, administered during the last 4 days (Days 25 to 28). Injections were administered subcutaneously in the morning 15 min before breakfast. Reduction from a given dose level was considered following two or more episodes of vomiting on > 2 consecutive days; and/or two or more episodes of marked nausea (of severe intensity for >2 h) on > 2 consecutive days. In each subject, decisions relating to dose progression were made by an investigator based on evaluation of blinded safety and tolerability data.
Each subject received three standardized test meals (breakfast, lunch and dinner) on Day−1 (1 day prior to study treatment) and on Day 28. The caloric content of each meal was~450 kcal with 50% energy as carbohydrate, 23% as fat and 27% as protein. For the determination of gastric emptying rate, 13 C-octanoic acid was added to the breakfast meal, as described below. Time zero was considered to be the beginning of the breakfast meal, which was consumed in 10 min. Blood glucose was determined at pre-specified time points with 24-hour profiling.
Assessments
At baseline, Day−1 and on the fourth day of each dose level, venous blood samples were collected at pre-specified times for measurement of blood glucose before and after the standardized breakfast, lunch and dinner. Blood glucose was determined at the bedside with a Yellow Springs Instruments 2300S glucose analyzer using the glucose oxidase method. Serum samples were analyzed for insulin and C-peptide concentration using radioimmunoassay methods (Linco Research Inc.). HbA 1c was analyzed using an immunological assay (Tina-quant® Hemoglobin A1C II, Roche Diagnostics, Germany). Change in HbA 1c was recorded from baseline to Day 29.
PPG-AUCs were calculated as the area under the time-concentration curve from 0:14 h after the morning injection, just before breakfast, until 4:55 h after the morning injection (PPG-AUC breakfast ), from 5:14 h after the morning injection (just before lunch) until 4:55 h after lunch (PPG-AUC lunch ) and from 10:14 h after the morning injection (just before dinner) until 4:55 h after dinner (PPG-AUC dinner ). Blood samples for determination of C-peptide, insulin and glucagon were collected on Day−1 and Day 28 after a standardized breakfast and were analyzed as the area under the time-concentration curve from 0:14 until 4:55 h (AUC) relative to the pre-breakfast value.
Gastric emptying
Gastric emptying at breakfast was determined by a 13 C-octanoic acid breath test [28] on Days−1 and 28. Patients received a standardized breakfast consisting of a scrambled egg with the yolk infused with 100 mg of 13 C-octanoic acid (manufacturer: Euriso-Top, France). The yolk and egg white were cooked separately, but administered together with two-and-a-quarter slices of white bread, 45 g low-fat cottage cheese, one teaspoon of margarine, a quarter teaspoon mayonnaise or olive oil, 100 g fruit yoghurt, and one apple or peach, followed immediately by 150 mL of non-sparkling water. The meal was consumed in less than 10 min. The rationale underlying the breath test methodology is that as a result of gastric emptying, the labeled octanoic acid reaches the duodenum (rate-limiting step), where it is rapidly absorbed and transported to the liver where it is oxidized, so that the 13 CO 2 / 12 CO 2 ratio over time provides a measure of gastric emptying [28] . End-expiratory breath samples were obtained immediately before the breakfast meal (baseline), then every 15 min for 2 h and then every 30 min for another 2 h using infrared isotope (IRIS)-breath bags (double-chamber) with a volume of 0.12 L (Wagner Analysen Technik, Bremen, Germany). The ratio of 13 CO 2 / 12 CO 2 in the breath was determined by IRIS analyzer (IRIS®, Wagner Analysen Technik, Bremen, Germany). These data were used to determine the 50% gastric emptying time (t 1/2 ).
Safety evaluation
Safety and tolerability assessments were based on adverse events, including symptomatic hypoglycemia (defined as an event with clinical symptoms that were considered to result from hypoglycemia), safety laboratory (standard hematology, clinical chemistry and urinalysis parameters), vital signs (blood pressure and pulse rate), 12-lead electrocardiogram (ECG), local tolerability at the site of injection, and anti-lixisenatide antibodies.
Statistical analyses
The primary analysis population was the modified intent-to-treat population, which included all patients who were randomized and received at least one dose of study medication. Patients who were randomized but not treated with study medication were not included in the analysis.
Demographic and background characteristics were summarized for the analysis population of all treated patients as well as by treatment group to assess the comparability of the treatment groups at baseline and to characterize the population. Continuous variables were summarized using the following descriptive statistics: number of patients (N), mean and standard deviation. Absolute and relative frequency distributions are provided for categorical data. Baseline demographic variables were tested for overall between-group homogeneity using all patients with available data. The continuous variables (age, BMI, time since diagnosis of diabetes and FBG) were compared using an analysis of variance model with treatment as fixed effect. The general association Cochran-Mantel-Haenszel test was used for categorical data such as sex and race. The statistical methods for the analysis of baseline data were used in a purely exploratory manner.
PPG-AUC at breakfast, lunch and dinner, maximum PPG and breakfast AUCs of C-peptide, insulin and glucagon concentration were analyzed using an analysis of covariance (ANCOVA) model with treatment as fixed effect and the corresponding baseline value (Day−1) as covariate. Least squares (LS) means and standard errors for the change from baseline and the difference between lixisenatide and placebo are provided.
Graphical presentations of the LS means with the corresponding standard error (SE) are provided together with p-values for the treatment comparisons (lixisenatide versus placebo), as well as the mean blood glucose concentration-time profiles.
On the ranked gastric emptying parameter t ½ , an ANCOVA model was applied with treatment as fixed effect and the corresponding ranked baseline value for t ½ , (Day−1) as a covariate. Descriptive statistics for t ½ were provided for 20 μg lixisenatide QD and placebo using the unranked values for t ½ . Statistical analyses were performed using SAS ® (SAS Institute, NC, USA).
The relationship between i) PPG-AUC breakfast and the x-fold change at Day 28 versus Day−1 (baseline) in gastric emptying (t ½ ), ii) AUC-C-peptide and PPG-AUC breakfast , iii) AUC-C-peptide versus the x-fold change at Day 28 versus Day−1 in gastric emptying (t ½ ), iv) the x-fold change at Day 28 versus Day−1 in gastric emptying (t ½ ), and v) PPG-AUC breakfast and gastric emptying at baseline (t ½ ) were all evaluated using linear regression analysis with GraphPad Prism (version 5.00 for Windows, GraphPad Software, San Diego California USA, www.graphpad.com). A p-value of less than 0.05 was considered significant in all analyses.
Results

Patient demographics and baseline characteristics
In total, 21 and 22 patients were randomized to lixisenatide and placebo, respectively. In the lixisenatide group, 19 patients achieved the maximum dose of 20 μg/day and were treated up to Day 28. Apart from a slightly higher proportion of obese patients (i.e. BMI ≥30 kg/m 2 ) in the lixisenatide group, demographic and baseline characteristics were generally comparable between the two treatment groups (Table 1) . Clinical characteristics, including HbA 1c and FBG at screening, were also comparable.
Safety and tolerability
There were no serious treatment-emergent adverse events and no signals identified from clinical laboratory tests, vital signs or ECG. The overall incidence of treatment-emergent symptomatic hypoglycemia was low (lixisenatide: two patients; placebo: one patient). One subject in the lixisenatide group had a hypoglycemic event considered by the investigator as severe, although the event did not fulfill the criteria for severe hypoglycemia and the subject recovered without the need for assistance. None of the hypoglycemic events led to discontinuation of study medication. Of note, there was a low incidence of nausea (two patients in each group) and no cases of vomiting in the lixisenatide group (two cases in the placebo group); diarrhea was reported by 4/21 patients with lixisenatide and no patients with placebo.
Blood glucose, serum insulin, C-peptide and glucagon
Lixisenatide 20 μg QD was associated with reductions versus placebo in PPG-AUC as well as maximum PPG (peak levels) from baseline (Day−1) to Day 28 following all three meals (breakfast, p b 0.0001; lunch, p b 0.001; and dinner, p b 0.05) ( Fig. 1 and Table 2 ). Hence, following administration of lixisenatide 20 μg QD in the morning, there was a significant pharmacodynamic effect on blood glucose levels throughout the day. With placebo, PPG-AUC from baseline to Day 28 was not affected after breakfast, and there was an increase in glucose levels following lunch and dinner at Day 28 compared with (Table 2) . Following breakfast, glucagon levels were reduced with lixisenatide compared with placebo (p b 0.01, Table 2 ).
Gastric emptying
Baseline gastric emptying (t ½ ) values were comparable for lixisenatide 20 μg QD and placebo. In the lixisenatide group, there was a marked increase in the gastric emptying t ½ versus baseline, while there was no difference in t ½ versus baseline in the placebo group (p b 0.01) ( Table 2) . (Fig. 2B) . Finally, there was a trend for an inverse correlation between C-peptide levels and gastric emptying (lixisenatide: r 2 = 0.16, ns; placebo: r 2 = 0.12, ns) (Fig. 2C) .
The changes in t ½ with lixisenatide 20 μg were inversely related to baseline t ½ , i.e. the magnitude of the slowing was greater when baseline gastric emptying was more rapid (r 2 = 0.39, p b 0.05) (Fig. 3A ).
An inverse correlation was also evident between PPG-AUC levels and baseline t ½ (r 2 = 0.37, p b 0.05) (Fig. 3B ).
Discussion
GLP-1 receptor agonists modulate gastrointestinal motility and slow gastric emptying in addition to their capacity to stimulate insulin and suppress glucagon secretion in a glucose-dependent manner [3, 4, 16] . Therefore, as postprandial glycemic excursions are determined by the rate of gastric emptying and insulin release is impaired in patients with T2DM, slowing gastric emptying is a valid approach to attenuate postprandial glycemic excursions and, thereby, to improve blood glucose control. Targeting both FBG and PPG levels is recognized to be pivotal for successful treatment of hyperglycemia [1] . However, as HbA 1c levels decrease as a result of diabetes therapy, consistent with the Monnier model, postprandial glycemia is considered to contribute to an increasingly greater extent to overall HbA 1c compared with pre-prandial/fasting glycemia [29] . Accordingly, control of postprandial glycemia is essential to achieve HbA 1c goals of b 7% or 6.5% [30] , which is reflected by the guidelines from the International Diabetes Federation for the management of postmeal glucose in diabetes [31] . Postprandial hyperglycemia may also be a direct, and independent, risk factor for cardiovascular diseases [32] . The current study evaluated the effects of lixisenatide, a new once-daily prandial GLP-1 receptor agonist for the treatment of T2DM, on PPG (AUC and peak levels) after standardized meals at breakfast, lunch and dinner, and on gastric emptying at breakfast, and the relationship between the effects on PPG and gastric emptying. The results indicate that in patients with T2DM on oral antidiabetic therapy, lixisenatide 20 μg administered once daily in the morning reduces PPG levels throughout the day, and that the reduction in PPG at least after breakfast is attributable to retardation of gastric emptying.
The effect of GLP-1 receptor agonists on gastric emptying has often been assessed using imprecise techniques such as the acetaminophen test [16, [33] [34] [35] . In this study, gastric emptying of breakfast was measured using the more accurate radiolabeled breath test technique and was shown to be markedly slowed by lixisenatide 20 μg QD when compared with placebo. Importantly, the magnitude of the reduction in PPG-AUC after breakfast was shown to be related closely to the degree of slowed gastric emptying ( Fig. 2A) and was not associated with a rise in insulin, supporting the concept that blunting PPG-AUC through GLP-1 receptor agonism can be achieved predominantly by slowing of gastric emptying [5] . The assumption that the reduced insulin response is related to the reduction in PPG-AUC is supported by the observed correlation between PPG and C-peptide (Fig. 2B ) and insulin levels (data not shown) for lixisenatide. There was also a trend for an inverse relationship between C-peptide ( Fig. 2C ) and insulin (data not shown) and retardation of gastric emptying. Hence, as is the case for native GLP-1 when administered exogenously, the slowing of gastric emptying induced by lixisenatide appears to outweigh its insulinotropic properties, at least after the first meal. Reduced glucagon levels following the breakfast meal (Table 2) were observed with lixisenatide compared with placebo. A reduction of postprandial glucagon secretion is a known effect of GLP-1 and GLP1 receptor agonists, which may contribute to the lowering of blood glucose concentrations [1] [2] [3] . Whether the reduction in PPG-AUC at subsequent meals also reflects inhibition of gastric emptying, and/or is a result of enhanced insulin release, glucagon suppression, or both, warrants evaluation.
Indirect comparison of the effects of lixisenatide with marketed GLP-1 receptor agonists, exenatide BID and LAR, and liraglutide QD, indicates that the impact on gastric emptying and resulting reduction in PPG-AUC are important differentiating characteristics within this class that are dependent on the pharmacokinetics of the individual agent. For the longer-acting GLP-1 receptor agonist liraglutide, there is evidence that the sustained 24-hour exposure results in receptor desensitization and tachyphylaxis to the slowing of gastric emptying which is within 2 weeks of treatment in rats [33] . These data are consistent with an apparently modest delay in gastric emptying, limited to 1 h post-meal, reported in patients with T2DM after 3 weeks of treatment with liraglutide [15] . A minor effect on gastric emptying has also been reported for exenatide LAR, which has been considered not to be of clinical relevance [36] . In contrast to longer-acting agents, and similar to the findings with lixisenatide, PPG levels and the slowing of gastric emptying are inversely correlated in patients with T2DM treated with the shorter-acting exenatide BID [5] . Although not reported in this paper, the changes from baseline for the gastric emptying half-time at breakfast were comparable after once-versus twice-daily dosing of lixisenatide i.e. 20 μg QD or BID (t 1/2 QD = 211.5 ± 278.50 min; t 1/2 BID = 202.3 ± 229.98 min). These data are consistent with the effect of BID administered exenatide and do not suggest desensitization/ tachyphylaxis to the slowing of gastric emptying with BID-dosing of lixisenatide. A sustained slowing of gastric emptying is, accordingly, likely to account for the observed greater reduction in PPG for the shorter-acting agents, for example in clinical head-to-head comparisons of exenatide BID versus liraglutide [37] and lixisenatide versus liraglutide [18] . The mean terminal half-life of approximately 3 h in humans characterizes lixisenatide as a shorter-acting GLP-1 receptor agonist, like exenatide BID. Lixisenatide is also characterized by a strong binding affinity to the GLP-1 receptor, which is approximately four-fold greater than the affinity of native GLP-1 [38] . The shorter half-life of lixisenatide combined with a strong affinity for the GLP-1 receptor may allow a distinct period of time between injections without receptor activation to circumvent the mechanism of tachyphylaxis and ensure a sustained effect to slow gastric emptying, resulting in a major reduction in PPG. These considerations are of relevance for the combination of a GLP-1 receptor agonist and basal insulin in T2DM patients. Complementing the FBG benefits of basal insulin with the greater PPGlowering effects of a shorter-acting GLP-1 receptor agonist may be more effective than combining with longer-acting agents that rely on a sustained insulinotropic effect and, like basal insulin products, predominantly reduce FBG. For patients with improved HbA 1c under therapy (including those on insulin treatment), who have a greater dependency on postprandial glucose, lixisenatide or exenatide BID are likely to be sound choices.
In summary, this study shows that in patients with T2DM, lixisenatide injection (20 μg) in the morning reduces postprandial glycemic excursions throughout the day, which (at least after breakfast) is accounted for by a sustained slowing of gastric emptying. 
Conclusions
Results from this randomized, double-blind, placebo-controlled, parallel-group study using an ascending dose range of (5-20 μg) increased every fifth day in increments of 2.5 μg demonstrated that lixisenatide 20 μg QD reduced PPG from baseline to Day 28 at all meals (breakfast, lunch and dinner). Gastric emptying (50% emptying time) increased substantially from baseline with lixisenatide 20 μg QD, but not with placebo. There was an inverse relationship between PPG-AUC following a standardized breakfast and gastric emptying with lixisenatide 20 μg QD. In conclusion, lixisenatide 20 μg QD reduced postprandial glycemic excursions in patients with T2DM, likely as a result of sustained slowing of gastric emptying.
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